Abstract:ConspectusCells, particularly living cells, serve as natural carriers of bioactive substances. Their inherent low immunogenicity and multifunctionality have garnered significant attention in the realm of disease treatment applications, specifically within the domains of cancer immunotherapy and regenerative tissue repair. Nevertheless, several prominent challenges impede their swift translation into clinical applications, including obstacles related to large-scale production feasibility and high utilization costs. To address these issues comprehensively, researchers have proposed the notion of bionic cells that are synthetically generated through chemical or biosynthetic means to emulate cellular functions and behaviors. However, artificial cell strategies encounter difficulties in fully replicating the intricate functionalities exhibited by living cells while also grappling with the complexities associated with design implementation for clinical translation purposes. The convergence of disciplines has facilitated the reform of living cells through a range of approaches, including chemical-, biological-, genetic-, and materials-based methods. These techniques can be employed to impart specific functions to cells or enhance the efficacy of therapy. For example, cells are engineered through gene transduction, surface modifications, endocytosis of drugs as delivery systems, and membrane fusion. The concept of engineered cells presents a promising avenue for enhancing control over living cells, thereby enhancing therapeutic efficacy while concurrently mitigating toxic side effects and ultimately facilitating the realization of precision medicine.In this Account, we present a comprehensive overview of our recent research advancements in the field of engineered cells. Our work involves the application of biological or chemical engineering techniques to manipulate endogenous cells for therapeutics or drug delivery purposes. For instance, to avoid the laborious process of isolating, modifying, and expanding engineered cells in vitro, we proposed the concept of in situ engineered cells. By applying a hydrogel loaded with nanoparticles carrying edited chimeric antigen receptor (CAR) plasmids within the postoperative cavity of glioma, we successfully targeted tumor-associated macrophages for gene editing, leading to effective tumor recurrence inhibition. Furthermore, leveraging platelet's ability to release microparticles upon activation at injury sites, we modified antiprogrammed death 1 (PD-1) antibodies on their surface to suppress postoperative tumor recurrence and provide immunotherapy for inoperable tumors. Similarly, by exploiting bacteria's active tropism toward sites of inflammation and hypoxia, we delivered protein drugs by engineered bacteria to induce cancer cell death through pyroptosis initiation and immunotherapy strategies. In the final section, we summarize our aforementioned research progress while providing an outlook on cancer therapy and the hurdles for clinical translation with potential solutions or future directions based on the concept of engineered cells.

Cell/Bacteria‐Based Bioactive Materials for Cancer Immune Modulation and Precision Therapy

Bacteria‐Based Cancer Immunotherapy

Advanced Biomaterials for Cell‐Specific Modulation and Restore of Cancer Immunotherapy

Bacterial-based cancer therapy: An emerging toolbox for targeted drug/gene delivery

Biomimetic and Materials-Potentiated Cell Engineering for Cancer Immunotherapy

Application of Bionanomaterials in Tumor Immune Microenvironment Therapy

Advanced Biomaterials for Cancer Immunotherapy

Advanced Biomaterials with Intrinsic Immunomodulation Effects for Cancer Immunotherapy

Emerging biomaterials for tumor immunotherapy

Engineering Cells for Cancer Therapy

Living Cell‐Derived Intelligent Nanobots for Precision Oncotherapy

Recent Advances in Bacteria-Based Cancer Treatment

Biomaterial-based platforms for modulating immune components against cancer and cancer stem cells

Nanomaterial-Based Drug Delivery Systems: A New Weapon for Cancer Immunotherapy

Bacteria-mediated Cancer Therapy: A Versatile Bio-Sapper with Translational Potential

The role of bacteria and its derived biomaterials in cancer radiotherapy

Current Status and Future Directions of Bacteria-Based Immunotherapy

Harnessing and Mimicking Bacterial Features to Combat Cancer: From Living Entities to Artificial Mimicking Systems

Bacteria-based bioactive materials for cancer imaging and therapy

Engineered Biomaterials for Cancer Immunotherapy

Nanobiohybrids: A Synergistic Integration of Bacteria and Nanomaterials in Cancer Therapy